Beyond Air Appoints Robert Goodman as its CEO
Beyond Air has appointed Robert Goodman as its new Chief Executive Officer, following the resignation of long-time CEO Steve Lisi, marking a significant leadership transition for the medical device and biopharmaceutical firm.
Lisi stepped down from both his executive role and the company’s board, bringing to a close nearly a decade of leadership during which he guided the company through critical phases of product development and commercialization.
During his nine-year tenure, Lisi played a central role in advancing the company’s flagship LungFit PH system, a nitric oxide-based technology designed to treat neonatal hypoxic respiratory failure.
The product secured both regulatory approval from the U.S. Food and Drug Administration and CE Mark certification, positioning the company as a player in specialized respiratory care.
Under his leadership, Beyond Air also transitioned into a commercial-stage organization, expanding its focus to explore nitric oxide applications across respiratory, neurological, and oncology segments.
Goodman’s appointment reflects a continuity-driven approach, with the company choosing a leader already embedded within its strategic and operational framework.
Having served as Chief Commercial Officer and a board member, Goodman brings familiarity with the company’s growth agenda and product pipeline. He joined the board in mid-2025 and moved into a commercial leadership role later that year.
Also Read: Jaishankar Meets Rubio, GCC Envoys Amid Energy Push
His prior experience spans senior roles at BioTelemetry, Philips Healthcare, Thermo Fisher Scientific, and Pfizer. He also serves on the board of Fourth Frontier and is a retired U.S. Army officer.
In his statement, Goodman emphasized opportunities to expand the adoption of nitric oxide technology across both domestic and international markets.
Also Read: HSBC Appoints David Rice as First Chief AI Officer
The leadership change comes at a challenging yet pivotal moment for Beyond Air.
The company currently operates with a relatively modest market capitalisation and has faced pressure in public markets, with its stock trading near its yearly lows. Despite these headwinds, analysts have indicated potential for revenue growth and a pathway to profitability in the near term.
Also Read: India, UK are Global AI Superpowers: Rishi Sunak
Recent financial updates suggest progress, including improved revenues and reduced operating costs, though the company continues to report net losses.